Objectives: To illustrate the progressive loss of cross-echinocandin activity on Candida albicans isolates with strong clonal homology from a patient with advanced HIV infection and chronic oesophagitis progressively resistant to uninterrupted micafungin treatment.
Introduction
Echinocandins are a new class of antifungal antibiotics with potent activity against Candida albicans in vitro, and with established clinical efficacy in the treatment of oesophageal candidiasis. [1] [2] [3] As with any new class of antimicrobial agents, the development of clinical resistance is an important concern, particularly given the increasing use of these new agents. Moudgal et al. 4 recently reported evidence of clinical failure and emergence of multiechinocandin resistance in vitro during therapy in a patient with a Candida parapsilosis prosthetic valve endocarditis. However, echinocandins have poor intrinsic in vitro activity against C. parapsilosis. [5] [6] [7] Hernandez et al. 8 have recently reported in a patient with a C. albicans oesophagitis emergence of in vivo and in vitro resistance during prolonged caspofungin treatment. We hereby report failure of micafungin observed during a 10 month course of therapy in a patient with C. albicans oropharyngeal and oesophageal candidiasis. Serially obtained isolates during therapy showed increased MIC values of caspofungin, micafungin and anidulafungin in association with the acquisition of mutations in the FKS1 gene that are characteristic of reduced echinocandin susceptibility.
Patient and methods

Case history
A 38-year-old man with a symptomatic and culture proven C. albicans oropharyngeal and oesophageal candidiasis refractory to azole therapy was started on compassionate micafungin. The patient had been HIV seropositive for 17 years, and his course had previously been complicated by Pneumocystis jiroveci pneumonia, cytomegalovirus retinitis . Three weeks before the initiation of micafungin, his HIV RNA plasma viral load was 44 819 copies/mL and his CD4 lymphocyte count was 5 cells/mm 3 of blood. A gastroscopy, 16 days after the initiation of micafungin, detected oesophageal candidiasis and resolution of the oropharyngeal lesions. Over a period of 10 months, the patient continuously received iv micafungin, 100 mg once daily for the first 2 days, 200 mg daily for 3 weeks and 400 mg daily for the remaining period. The patient noted partial relief of the dysphagia within 2 days of starting therapy and an even greater relief once the dose of micafungin was increased to 400 mg daily. Despite the initial improvement in therapy, by 5 months after the initiation of micafungin, the patient noted increasingly frequent recurrences of oropharyngeal candidiasis. By 7 months of micafungin therapy, he again complained of progressive dysphagia and weight loss. Oral itraconazole was empirically added with no significant clinical improvement. After nearly 10 months of therapy, surgical implantation of a new venous access was required; the procedure was complicated by a pneumothorax and the patient had an unexpected cardiac arrest and died when a chest tube was inserted. During the course of treatment with micafungin, his HIV infection remained poorly controlled despite several changes in his antiretroviral therapy.
Fungal isolates
Isolates of C. albicans were recovered from the patient's oropharyngeal cultures on three different occasions as follows: at the time of initiation of micafungin therapy, at week 6 and at week 36 of treatment. At week 36, two phenotypically different isolates were recovered from culture.
The isolates were all identified as C. albicans by means of germ tube and chlamydospore formation and by the Vitek YBC identification system (BioMérieux).
Antifungal susceptibility testing of each isolate was performed by a broth microdilution method. For amphotericin B, itraconazole, fluconazole, voriconazole, ravuconazole and posaconazole, susceptibilities were determined according to the guidelines recommended by the CLSI in document M27-A. 9 Susceptibilities to caspofungin, micafungin and anidulafungin were performed according to the recommendations reported by Odds et al.
10 MIC endpoints were determined using the visual 'prominent growth reduction' (MIC-2) criteria measured at 24 h in RPMI 1640 medium. C. parapsilosis ATCC 22019 and Candida krusei ATCC 6258 were used for quality control.
FKS1 mutations conferring reduced susceptibility to echinocandin drugs were determined by DNA sequence analysis of a region of the CaFKS1 that was recently shown to confer reduced susceptibility in both laboratory strains and clinical isolates of C. albicans.
11
The sense and antisense primers used for PCR and sequencing, based on CaFKS1 sequence (GenBank accession no. D88815), were 5 0 -CATTGCTGTGGCCACTTTAG-3 0 and 5 0 -GGTCAAATCAGT-GAAAACCG-3 0 , respectively. The PCR products were purified, quantified by fluorescence labelling (Pico Green, Molecular Probes) and sequenced in both the 5 0 and 3 0 directions using the DTCS Quick Start Kit (Beckman Coulter).
Multilocus sequencing typing (MLST) was performed on each of the isolates as previously described. 12, 13 For each gene, distinct alleles were identified and numbered using the non-redundant databases program (http://calbicans.mlst.net/). The alleles at each of the six loci constituted a strain's allelic profile, i.e. diploid sequence type (DST). Each distinct allelic profile was considered a unique DST or genotype. An unweighted pair group method with arithmetic mean (UPGMA) dendrogram based on the pair-wise differences in the allelic profiles of the six genes was constructed using the START program (http://www.medawar.ox.ac.uk/maiden/software.shtml).
The discriminatory power was measured with Simpson's index of diversity. Genotypes for MLST were based on individual DSTs.
Results and discussion
In a patient with C. albicans oesophagitis refractory to triazole and polyene therapy, the use of an echinocandin appears warranted. Micafungin (which had not yet been approved at the time it was started) was selected because of its higher tolerable dosage. 14, 15 The MIC values for sequential C. albicans isolates recovered at baseline and during therapy are shown in Table 1 . At baseline, the MICs of micafungin, caspofungin and anidulafungin were all £0.06 mg/L. Within 6 weeks of treatment, MIC values of all three echinocandins increased >33-fold and remained constant throughout the remaining 7.5 months of micafungin treatment. DNA sequencing of the known mutational 'hot spot' regions of the FKS1 gene correlated with the increases in the MIC values (Figure 1 ). Two prominent Fks1p mutations, S645F and R1361H, known to confer reduced echinocandin susceptibility in C. albicans 11 were identified in the week 6 and week 36 isolates. All four fluconazole-resistant isolates had a homozygous F145L mutation in the triazole target gene ERG11 and 11-to 74-fold increases in transcript levels of the multidrug efflux pump genes CDR1 and CDR2 relative to the azole-susceptible reference strain ATCC 90028 (Table 2 ). Strong clonal homology of all four isolates was supported through MLST analysis showing identical allelic profiles genetically distinct from five other geographically diverse strains (Figure 2 ).
Exposure to antimicrobial agents is an important triggering factor in the emergence of drug resistance. Little is known about the development of C. albicans echinocandin resistance in the clinical setting. Hernandez et al. 8 reported a C. albicans thrush-oesophagitis refractory to caspofungin that was associated with increased caspofungin MIC. Our observation documents a similar phenomenon with another echinocandin, but with simultaneous loss of activity by all three echinocandins (micafungin, caspofungin and anidulafungin), suggesting a common mechanism for reduced susceptibility, as recently reported. 11 However, it is of interest to note that our patient had been treated with caspofungin during 10 consecutive months in the year that preceded the beginning of the treatment with micafungin. Unfortunately, caspofungin susceptibility of the C. albicans isolates was not determined during that previous period of exposure to caspofungin. Yet the baseline isolate recovered at the onset of the micafungin treatment showed low MICs of all three echinocandins including caspofungin and absence of FKS1 gene mutations. Whether a loss of resistance occurred during the 2 months free of any echinocandin exposure will remain unknown. The sequential increments in the dose of micafungin used in our patient may have favoured the emergence of FKS1 mutants and progressive increase of the MICs observed throughout the treatment period. The relative potentials of the various echinocandins to trigger in vivo resistance mutations are unknown and may vary from one agent to the other. Finally, despite a global correlation between the in vitro loss of activity and the poor clinical response observed in our patient, it is interesting to note that there was a time gap between their respective manifestations. Indeed the in vitro loss of activity was manifested 14 weeks before the documentation of micafungin clinical failure despite no obvious change in the patient's antiretroviral therapy or general immunosuppressive status.
In conclusion, echinocandins are potent, well-tolerated antifungal drugs with good clinical efficacy and low toxicity profiles. Given the paucity of antifungal drugs, their use in clinical situations represents an attractive alternative. Our report and that of others raise concern for potential loss of activity following extensive clinical exposures. Echinocandin loss of activity
